Aspira Women’s Health (NASDAQ:AWH) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research lowered shares of Aspira Women’s Health (NASDAQ:AWHGet Rating) from a hold rating to a sell rating in a report issued on Monday morning, Zacks.com reports.

According to Zacks, “Aspira Women’s Health Inc. engaged in the discovery, development and commercialization of testing options and bio-analytical solutions for women’s health. Aspira Women’s Health Inc., formerly known as Vermillion Inc., is based in AUSTIN, Texas. “

Shares of Aspira Women’s Health stock opened at $0.58 on Monday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.82 and a current ratio of 4.85. Aspira Women’s Health has a 1 year low of $0.32 and a 1 year high of $6.25. The business has a 50 day moving average price of $0.88 and a 200 day moving average price of $1.41.

Aspira Women’s Health (NASDAQ:AWHGet Rating) last issued its quarterly earnings results on Wednesday, May 11th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). Aspira Women’s Health had a negative return on equity of 102.03% and a negative net margin of 485.64%. During the same period in the prior year, the firm posted ($0.05) earnings per share. On average, analysts anticipate that Aspira Women’s Health will post -0.33 EPS for the current year.

A number of hedge funds have recently modified their holdings of AWH. Royal Bank of Canada raised its stake in shares of Aspira Women’s Health by 57.3% in the 2nd quarter. Royal Bank of Canada now owns 9,347 shares of the company’s stock valued at $53,000 after purchasing an additional 3,403 shares in the last quarter. Citigroup Inc. boosted its holdings in Aspira Women’s Health by 58.6% during the third quarter. Citigroup Inc. now owns 9,211 shares of the company’s stock worth $30,000 after buying an additional 3,405 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Aspira Women’s Health by 35.1% during the third quarter. Principal Financial Group Inc. now owns 15,701 shares of the company’s stock worth $51,000 after buying an additional 4,077 shares in the last quarter. Invesco Ltd. boosted its holdings in Aspira Women’s Health by 26.7% during the third quarter. Invesco Ltd. now owns 30,504 shares of the company’s stock worth $99,000 after buying an additional 6,434 shares in the last quarter. Finally, Balyasny Asset Management LLC purchased a new stake in shares of Aspira Women’s Health in the 3rd quarter valued at approximately $34,000. Hedge funds and other institutional investors own 54.01% of the company’s stock.

About Aspira Women’s Health (Get Rating)

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer.

Featured Articles

Get a free copy of the Zacks research report on Aspira Women’s Health (AWH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with MarketBeat.com's FREE daily email newsletter.